MERCK & CO, INC. for MERCK & CO INC
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling; Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Vaccine Policy; Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| STEPHANIE MCBATH | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
| BRADFORD TALLAMY | — |
Medicare/Medicaid MMM
Issues relating to, One Big Beautiful Bill Act (P.L. 119-21), issues related to health care; Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Medicaid drug rebate program Cost and value of medicines: Drug pricing and reimbursement issues; FY-2026 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP).
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
| BRADFORD TALLAMY | — |
Taxation/Internal Revenue Code TAX
Issues relating to, Tax reform and tax policy, generally; Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
Animals ANI
Issues relating to, Agriculture; Animal Health Technology; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Rural development; Administration and related agencies appropriations bill, FY-26.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHANIE MCBATH | — |
| BRADLEY ALLEN ROSSIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.